GlassScriptPhysician profile
Matthew Shane
NPI 1407894850
$832.68
in general payments reported to CMS, 2019-2025
11 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.21 · 2020: $43.95 · 2021: $132 · 2022: $163 · 2023: $145 · 2024: $106 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $279.48 | 2019-2024 | Phasix Mesh |
| Integra Lifesciences Corporation | $166.67 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medtronic, INC. | $144.74 | 2023 | Valleylab Ft10 |
| Intuitive Surgical, INC. | $52.43 | 2024-2025 | |
| Ethicon US, LLC | $48.15 | 2021 | |
| Innovation Technologies INC | $44.19 | 2024 | Irrisept |
| Takeda Pharmaceuticals U.S.A., INC. | $22.95 | 2022 | |
| Tela Bio, INC. | $22.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.24 | 2024 | |
| Innocoll Pharmaceuticals Limited | $16.36 | 2022 | |
| W. L. Gore & Associates, INC. | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.